Overactive Bladder - Results from #1600

Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia - Abstract September 3, 2014

The evaluation and management of refractory neurogenic overactive bladder - Abstract September 2, 2014

The role of mirabegron in overactive bladder: A systematic review and meta-analysis - Abstract September 1, 2014

AUGS Committee Opinion: OnabotulinumtoxinA and the bladder September 1, 2014

Proof of concept trial on changes in current perception threshold after sacral neuromodulation - Abstract August 29, 2014

Impact of sympathetic dysfunction in the etiology of overactive bladder in women: A preliminary study - Abstract August 28, 2014

Efficacy of the β3-adrenoceptor agonist mirabegron for the treatment of overactive bladder by severity of incontinence at baseline: A post hoc analysis of pooled data from three randomised phase 3 trials - Abstract August 27, 2014

Intra-detrusor injection of botulinum toxin for female refractory idiopathic overactive bladder syndrome - Abstract August 27, 2014

Overactive Bladder Treatments Behavioral and Pharmacologic August 25, 2014

Long term safety of sacral nerve modulation in Medicare beneficiaries - Abstract August 22, 2014

Healthcare resource use and costs of privately insured patients who switch, discontinue, or persist on anti-muscarinic therapy for overactive bladder - Abstract August 22, 2014

Are oxybutynin and trospium efficacious in the treatment of detrusor overactivity in spinal cord injury patients? - Abstract August 21, 2014

Bladder instillation of liposome encapsulated onabotulinumtoxinA improves overactive bladder symptoms- a prospective multi-center double blind randomized trial - Abstract August 20, 2014

Chapter 2: Pathophysiology of neurogenic detrusor overactivity and the symptom complex of "Overactive bladder" - Abstract August 18, 2014

Practical aspects of administration of onabotulinumtoxinA - Abstract August 15, 2014

Chapter 5: Clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB) - Abstract August 15, 2014

Chapter 4: Guidelines for the diagnosis and treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO) - Abstract August 13, 2014

Mirabegron 50 mg once-daily for the treatment of symptoms of overactive bladder: An overview of efficacy and tolerability over 12 weeks and 1 year - Abstract August 12, 2014

National Government Services issues positive coverage for percutaneous tibial nerve stimulation August 11, 2014

Lower urinary tract symptoms: Thinking beyond the urinary tract - Abstract August 11, 2014

Page 81 of 122